



ACPE 2025

**ISPE's 17th Asian Conference on
Pharmacoepidemiology**

21 - 23 November 2025 • Hong Kong


Conference

Program Book



Welcome Message

Welcome from the ACPE 2025 Local Host Chair & Conference Co-Chair



Dear colleagues and friends,

It is my great pleasure to welcome you to Hong Kong for the 17th Asian Conference on Pharmacoepidemiology (ACPE 2025), co-hosted by The International Society of Pharmacoepidemiology (ISPE) and The University of Hong Kong (HKU).

The scientific programme features distinguished international experts who will share insights on the latest research, emerging trends, and key challenges. We are also delighted to provide a platform for students and early-career researchers to present their work through oral presentations, posters and interactive sessions. Alongside academic discussions, the conference facilitates networking with peers, industry partners and government representatives fostering collaborations that drive progress in drug safety and outcomes research across pharmacoepidemiology, pharmacovigilance and data sciences.

The Centre for Safe Medication Practice and Research (CSMPR) at The University of Hong Kong has led ongoing contributions in pharmacovigilance research since its establishment in 2012. This conference serves as a pivotal platform to advance global collaborations in evidence-based practice and policy decision-making. We are particularly excited to host this event in Hong Kong, a vibrant international city that beautifully blends Eastern and Western cultures. Beyond the conference sessions at HKU, I hope you'll have time to experience Hong Kong's unique energy, from its spectacular harbour views to its rich culinary traditions.

I welcome delegates from across Asia-Pacific, Europe, and North America for what promises to be both a scientifically enriching and personally memorable experience. To our partners at The International Society of Pharmacoepidemiology (ISPE), all speakers, attendees and sponsors, we extend our sincere gratitude for your support of this important initiative. Your participation will help advance the fields of pharmacoepidemiology, pharmacovigilance and data sciences and their impact on health.

I welcome you all.

Warm regards,

Professor Esther W.Y. Chan

Local Host Committee Chair & Conference Co-Chair
Assistant Dean (Health Sciences Education)
Department of Pharmacology and Pharmacy
Co-Director, Centre for Safe Medication Practice and Research
Li Ka Shing Faculty of Medicine
The University of Hong Kong

Welcome Message

Message from the Chair, ACPE International Steering Committee



As Chair of the ACPE International Steering Committee at the International Society for Pharmacoepidemiology (ISPE), I am delighted to welcome you all to ACPE 2025 in Hong Kong. Last year's conference in Tokyo saw a record number of abstract submissions, and this year, that record has been surpassed once again, setting a new milestone in the history of ACPE. This continued growth reflects the remarkable development of pharmacoepidemiology across Asia, driven by the steady expansion of research teams and the strengthening of scientific capacity in many countries throughout the region, as real-world evidence continues to play an increasingly important role in healthcare improvement.

Over more than two decades, ACPE has developed into a vital platform connecting academia, industry, and regulatory authorities to promote collaboration and scientific excellence in pharmacoepidemiology. The dedication and teamwork among colleagues throughout the region have been instrumental in driving this progress and nurturing the next generation of researchers.

I would like to express my sincere appreciation to the Local Host Committee for their outstanding efforts in organizing this conference, and to all participants for contributing to the ongoing success and impact of ACPE.

Professor Hiraku Kumamaru

ISC Chair & Conference Co-Chair
Department of Health Data Science
Graduate School of Data Science
Yokohama City University, Japan

Welcome Message

From ISPE President

On behalf of the International Society for Pharmacoepidemiology (ISPE), it is my great pleasure and honour to warmly welcome you all to the 17th Asian Conference on Pharmacoepidemiology (ACPE) here in Hong Kong!



We are delighted to co-host this important meeting together with the University of Hong Kong (HKU). This partnership reflects not only the strength of collaboration between institutions but also the vital role of open exchange, shared learning, and mutual support in advancing pharmacoepidemiology—particularly in times that call for resilience and innovation.

This year's conference brings together researchers, practitioners, and experts from across Asia and around the globe. By uniting diverse disciplines and perspectives, we hope to strengthen scientific dialogue, foster meaningful connections, and broaden the impact of pharmacoepidemiology in improving health worldwide. Throughout the meeting, you will have the opportunity to deepen your knowledge through engaging educational sessions, gain fresh insights from inspiring keynote lectures and symposia, and explore the breadth of research presented in our paper sessions.

Equally important, ACPE is a place to connect with colleagues, meet new friends, and lay the foundation for future collaborations. Our social program is designed to encourage networking in a relaxed setting, and we warmly invite you to take part in these activities. And of course, beyond the conference itself, Hong Kong offers a truly unique backdrop: a vibrant city where tradition and modernity meet, rich with cultural landmarks, historic neighbourhoods, and endless opportunities to enjoy world-class cuisine and experiences.

I would like to warmly thank the organisers of the conference, and especially the conference co-chairs, Professor Hiraku Kumamaru from Yokohama City University and Professor Esther W.Y. Chan from the University of Hong Kong, for their outstanding efforts and dedication in making this conference a success.

We are thrilled to welcome you—not only to this conference, but also to a community dedicated to advancing our field together.

Welcome to Hong Kong, and welcome to the 17th Asian Conference on Pharmacoepidemiology!

Warm regards,
Ursula Kirchmayer
President of ISPE

Educational Session Venue

Friday 21 November 2025

Cyberport

Cyberport, Cyberport 3, 100 Cyberport Road, Hong Kong



Room	Session
Foyer Core E	REGISTRATION DESK
Function Room 1 Core E	TRACK A: DATABASE PHARMACOEPIDEMIOLOGY (INTRODUCTORY/INTERMEDIATE)
Smart Living Lab 3 Core C	TRACK B: NON-DATABASE PHARMACOEPIDEMIOLOGY (INTRODUCTORY/INTERMEDIATE)
Function Rooms 2 Core E	TRACK C: ARTIFICIAL INTELLIGENCE TOOLS TO SUPPORT PHARMACOEPIDEMIOLOGY RESEARCH
Training Theatre Core F	TRACK D: ADVANCED PHARMACOEPIDEMIOLOGY
Smart Living Lab 2 Core C	ISPE BOARD MEETING

[Download the directions to the individual rooms in Cyberport.](#)

Wi-Fi

"Cyberport_Openwifi" is available for visitors.

24 hour access is available once you have accepted the terms and conditions.

Catering

Morning and afternoon tea will be provided.

Lunch will not be provided. Attendees can purchase their lunch from one of the many food venues located in Cyberport Arcade.

<https://arcade.cyberport.hk/dining>.

Two Day Conference Venue

Saturday 22 and Sunday 23 November 2025

The University of Hong Kong Medical Campus

3 and 5 Sassoon Road, Pokfulam, Hong Kong



Two Day Conference Venue

Saturday 22 and Sunday 23 November 2025

The University of Hong Kong Medical Campus

3 and 5 Sassoon Road, Pokfulam, Hong Kong

3 Sassoon Rd	
Lecture Theatre 2, 1/F	Conference Opening and Welcome Addresses Keynote Presentation: Amy Chan Oral and Symposia sessions AsPEN Showcase Keynote Presentation: Mary Beth Ritchey Awards Presentations and Conference Close
Lecture Theatre 1, 1/F	Conference Opening and Welcome Addresses (overflow) Keynote Presentation: Amy Chan (overflow) Oral and Symposia sessions
Foyer, 1/F-3/F	Posters and catering
Learning Commons A, 1/F	VIP room Speaker preparation room
Learning Commons B, 1/F	Spotlight poster presentations Catering
Room 402, 4/F	Speaker preparation room
Room 403, 4/F	Available to book for ad hoc meetings
5 Sassoon Road	
SR1A, G/F	Spotlight poster presentations
SR1B, G/F	Available to book for ad hoc meetings
SR2, G/F	Catering
SR3, G/F	Poster presentations Catering

IMPORTANT! The University of Hong Kong is a smoke-free Campus. There is a total smoking ban, both indoors and outdoors.

[Download the directions to the HKU Medical Campus](#)

Wi-Fi

Visitors may choose to use "Wi-Fi.HK via HKU" whilst on the HKU campus.

Catering

Morning and afternoon tea and lunches will be provided.

To assist with delegate flow and comfort, catering stations will be located over various rooms and spaces. Your name badge will identify the catering station that we ask you to attend.

General information

Registration at the venues

Please print your 'name badge confirmation email' which contains your QR code and bring this with you to the conference for check-in.

Upon your first arrival at either one of the following venues, please proceed to the self-service printers to generate your conference name badge and dinner ticket (if purchased).

1. Cyberport, Core E, Level 3 Foyer
2. Delaney's Restaurant, Cyberport
3. The University of Hong Kong, 3 Sassoon Road, 1/F

Scan your QR code for automatic name badge printing.

Attach a blue lanyard to your name badge.

If you have any problems printing your name badge, staff will be available to assist you.

There is no additional registration process and you do not need to check-in with event staff. You may then proceed to the conference room.

You do not need to register again on the following days, but please make sure you bring your name badge with you.

You **MUST** wear your name badges at all times for access to the conference venues.

Certificate of Attendance

Attendees will be emailed a certificate of attendance during the week following the conference. If you presented a poster or contributed oral paper, this will be included on your certificate.

SIM cards

Local SIM cards can be purchased at various convenience stores and supermarkets.

Organising Committees

Local Host Committee

Esther Chan (ACPE Chair)

Joe Blais

Celine Chui

Shirley Li

Candy Ng

Eric Wan

Local Student Chapter

Vincent Yan (President)

Eunice Deng (Vice-president)

Jack Lau (Secretary)

Tina Tian (Treasury)

Program Committee

Esther Chan (ACPE Chair)

The University of Hong Kong

Edward Lai

FISPE, National Cheng Kung University

Ben Bates

Rutgers University

Kai-Li Law

Merck

Joe Blais

The University of Hong Kong

Hu Li

Gilead Sciences

Sri Harsha Chalasani

JSS College of Pharmacy

Shirley Li

The University of Hong Kong

Nam-Kyong Choi

Ewha Womans University

Joshua Lin

Harvard

Celine Chui

The University of Hong Kong

Minako Matsumoto

Keio University School of Medicine

Ben Daniels

UNSW

Frank May (ISC Vice Chair)

FISPE

Juliana de Oliveira Costa

UNSW

Soko Setoguchi (ISC Past Chair, ISC Vice Chair)

FISPE, Rutgers University

Na-young Jung

Ewha Womans University

Krishna Undela

National Institute of Pharmaceutical Education and Research

Hiraku Kumamaru (ISC Chair)

Yokohama City University

Eric Wan

The University of Hong Kong

ISPE ACPE International Steering Committee

Hiraku Kumamaru (ISC Chair)

Yokohama City University

Ben Bates

Rutgers University

Esther Chan

The University of Hong Kong

Arnold Chan

FISPE, National Taiwan University

Edward Lai

FISPE, National Cheng Kung University

Nam-Kyong Choi

Ehwa Women's University

Jennifer Christian

FISPE, ISPE Vice President/Finance

Parthasarathi Gurumurthy

Pharmacovigilance Program

Yea-Huei Kao Yang

FISPE, National Cheng Kung University

Ursula Kirchmayer

FISPE, ISPE President Elect

Kiyoshi Kubota

FISPE, President Japanese Society for Pharmacoeconomics

Suk-Hyang Lee

Ajou University

Hu Li

Gilead Sciences

Kai-Li Liaw

Merck Inc.

Joshua Lin

Harvard

Meiyou Liu

4th Military Hospital University

Frank May (ISC Vice Chair)

FISPE

Jingping Mo

Pfizer Inc.

Nobuhiro Ooba

The Nihon University School of Pharmacy

Jingping Mo

Pfizer Inc.

Nobuhiro Ooba

The Nihon University School of Pharmacy

Jung-Won Park

Yonsei University

Byung Joo Park

FISPE, Korea Institute of Drug Safety & Risk Management

Sallie Pearson

UNSW Sydney

Syd Phillips

QuintilesIMS

Lisa Pont (ISPE Past President)

FISPE, University of Technology Sydney

Mary Beth Ritchey (ISPE Immediate Past-President)

FISPE, Rutgers University

Maribel Salas

FISPE, ISPE Global Development Committee

Savitha Sanathan

JSS College of Pharmacy, Mysore

Soko Setoguchi (ISC Past Chair, ISC Vice Chair)

FISPE, Rutgers University

Masato Takeuchi

Kyoto University

Shiro Tanaka

Kyoto University

Krishna Undela

National Institute of Pharmaceutical Education and Research

Sawaeng Watcharathanakij

Ubon Ratchathani University

Ian Chi Kei Wong

The University of Hong Kong

Siyan Zhan

Peking University

Wei Zhou

FISPE, Merck Inc.

Abstract reviewers

Sincere thanks to those who participated as an abstract reviewer. Their expert evaluation, thoughtful feedback, and dedication to maintaining the highest scientific standards was instrumental in ensuring the quality and excellence of the conference proceedings.

Ravinandan A P
Mohith Kumar Abaka
Kenji Adachi
Ramesh Adepu
Kehinde Adeyemi
Mohammad Adil
Kamakshi Shriya Akalu
Nouf Al-Fadel
Dana Alsugeir
Elstin Anbu Raj S
Kirsty Andresen
Chippy Anna Joy
Keiko Asao
Deepthi Avvaru
Zhaohui Bai
Mohammad Bakhriansyah
Shamala Balan
Tejaswini Baral
Benjamin Bates
Ruby Benson
Ramesh Bhandari
Saroj Bharti
Mohitosh Biswas
Joe Blais
Sri Harsha Chalasani
Sze Ling Chan
Chia-Hsien Suzu Chang
Raushan Kumar Chaudhary
Nai-Yu Chen
Lei Chen
Hung-Kai Chen
Yu-Chien Chen
Chi-Han Cheng
Dujrudee Chinwong
Jignasa Chiramana
Yongtai Cho
Nam-Kyong Choi
Ravindra Choudhary
Mehul Chourasia
Albert Tzu-Ming Chuang
Celine Chui
Shilpa Clara Joseph
Ben Daniels
Juliana De Oliveira Costa
Harriet Dickinson
Rakesh Dixit
Chengxiang Du
Hideki Endo
Min Fan
Guoze Feng
Saraswathy Ganesan Rajalekshmi
Le Gao
Stewart Geary
Louise Goh

Swarnali Goswami
Benjamin Grenier
Shalak Gunjal
Serena Jingchuan Guo
Vishawas H
Shota Hamada
Xintong He
Na He
Omar Hegazi
Chieh Yu Ho
Qingqing Hu
Rong Hua
Yinan Huang
Hsuan-Yu Hung
Chun-Tse Hung
Angelin Jaimon Augustine
Jessica Jalbert
Sudi Indra Jaya
Nisha Jha
He Jin
Sruthy Jose
Sun-Young Jung
Kyungyeon Jung
Wei Kang
Raju Kanukula
Mahmathi Karuppannan
Avinash Khadela
Seok-Won Kim
Bonggi Kim
Ju Hwan Kim
Ursula Kirchmayer
Hwa Yeon Ko
Hiraku Kumamaru
Prasanna Kumar
V Udaya Kumar
Litty Kunjumon
Akanksha Lahiri
Edward Lai
Yunfeng Lai
Hsi-Yu Lai
Jack Chi-Him Lau
Jasmine Lee
Wen Shi Lee
Shirley Li
Brian Li
Piaopiao Li
Hu Li
Hailong Li
Jieni Li
Silvia Tung Hiu Li
Yujia Li
Xinchi Li
Kevin Yi-Chen Liao
Yuexi Liao

Audrey Lim
Tengfei Lin
Jialing Lin
Shanshan Lin
Zhen-Fang Lin
Olivia Liu
Navin Kumar Loganadan
Alkesh Lokhande
Chinmaya Mahapatra
Eswaran Maheswari
Srikanth Malavalli Siddalingegowda
Kenneth Man
Uday Venkat Mateti
Dr Prithpal Singh Matreja
Minako Matsumoto
Frank May
Bitu Mesgarpour
Jingping Mo
Daniela Moga
Pranay Mohanty
Sharanya Murty
Sri Ram Muruges
Gouri Nair
Sreedharan Nair
Ding Quan Ng
Kaori Nomura
Marzieh Nosrati
Suguru Okami
Zacchaeus Olofin
Kazeem Adeola Oshikoya
Hasik P N
Yoshita Paliwal
Byung-Joo Park
Jaeyu Park
Lisa Pont
Basavaraj Poojar
Varsha Prabhu
Rajeshwari Puneekar
Irma Melyani Puspitasari
Jingjing Qian
Rosy Raju
Darmendra Ramcharran
Prity Rani
Mahesh Rathod
Ajaree Rayanakorn
Sanika Rege
Mita Restinia
Ramin Rezaeianzadeh
Judit Riera Arnau
Mary Beth Ritchey
Giuseppe Roberto
Catherine Rogers Murray
Libby Roughead
Manohar S K

Abstract reviewers (Cont'd)

Sincere thanks to those who participated as an abstract reviewer. Their expert evaluation, thoughtful feedback, and dedication to maintaining the highest scientific standards was instrumental in ensuring the quality and excellence of the conference proceedings.

Sujit Kumar Sah
Nurrul Salwa Saleh
Siti Watiqah Samsuddin
Chiranjeev Sanyal
Surasak Saokaew
Jyotirmoy Sarker
Balaji Sathyanarayana Gupta
Juny Sebastian
Atiqulla Shariff
Wen-Yi Shau
Meng Shu
Zuha Shyma
Yufei Song
Sathvik Sridhar
Elizabeth Stettenbauer
Hsuan-Yu Su
Swathi Suresh
Jehath Syed
Sumaiya Taj

Masato Takeuchi
Michelle Tan
Yonas Tefera
Christy Thomas
Wenya Tian
Duong Tran
Caroline Trin
Daniel Hsiang-Te Tsai
Krishna Undela
Ann Vazhayil Kuruvilla
Sona Vincent
Santosha Vooradi
Duy Vu
Eric Wan
Yan Wang
Grace Wangge
Kai Wei
Tao Wu
Shuang Xia

Li Xie
Takanori Yanai
Aimin Yang
Bo Ram Yang
Avery Shuei-He Yang
Lanting Yang
Alfi Yasmina
Gu Ye
See-Hwee Yeo
Naohiro Yonemoto
Beema Yoosuf
Abdelrahman Younis
Qiuyan Yu
Yan-Ning Zeng
Qishi Zheng
Wenfang ZhongJifang Zhou
Summera Qiheng Zhou
Bingbing Zhu
Che Zin

AMGEN | 安進香港

創**新**生物科技醫藥
引領治療新時代



想了解更多安進香港更多
請掃描

Q Amgen HK

HKD-NP-0425-80002 May-2025

Educational Session Program

Friday 21 November 2025

TRACK A: DATABASE PHARMACOEPIDEMIOLOGY (Introductory/Intermediate) (English)

Session coordinators:

Dr Benjamin Daniels, Senior Research Fellow, School of Population Health, University of New South Wales

Dr Celine Sze Ling Chui, Assistant Professor, School of Nursing, The University of Hong Kong

Instructors:

Prof Arnold Chan, FISPE, National Taiwan University

Dr Edmund Cheung, PDF, HKUMed, The University of Hong Kong

Dr Min Fan, PDF, HKUMed, The University of Hong Kong

Dr Le Gao, Assistant Professor, Xian Jiaotong University

Dr Benjamin Daniels, Senior Research Fellow, School of Population Health, University of New South Wales

Dr Stella Talic, Senior Lecturer, School of Public Health and Preventive Medicine, Monash University

Dr Vincent Yan, HKUMed, The University of Hong Kong

Time	Topic
08:30 – 09:00 (30 mins)	Designing pharmacoepidemiologic studies from clinical questions Instructor: Prof Arnold Chan
09:00 – 10:30 (90 mins)	Principles of pharmacoepidemiology using large databases: - Use of healthcare databases for pharmacoepidemiology research - Cohort study design and estimating drug exposure within healthcare databases Instructors: Dr Celine Chui and Dr Stella Talic
10:30 – 11:00 (30 mins)	BREAK
11:00 – 12:30 (90 mins)	Evaluation of clinical outcomes in healthcare databases: - Evaluation of clinical outcomes in healthcare databases - Bias and confounding - Thought exercise using healthcare databases to answer a clinical question Instructors: Dr Le Gao and Dr Edmund Cheung
12:30 – 13:30 (60 mins)	LUNCH on your own
13:30 – 15:00 (90 mins)	Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology- From Research Question to Protocol Instructor: Dr Benjamin Daniels
15:00 – 15:30 (30 mins)	BREAK
15:30 – 17:00 (90 mins)	Practical skills in protocol writing and statistical analytic programming in pharmacoepidemiology – From Protocol to SAS / R Programming Instructors: Dr Min Fan and Dr Vincent Yan
17:00	CLOSE

Educational Session Program

Friday 21 November 2025

TRACK B: NON-DATABASE PHARMACOEPIDEMIOLOGY (Introductory/Intermediate) (English)

Session coordinator:

Krishna Undela, National Institute of Pharmaceutical Education and Research (NIPER)

Instructors:

Krishna Undela, National Institute of Pharmaceutical Education and Research (NIPER)

Yinghui Liu, Merk

Time	Topic
08:30 - 09:00 (30 mins)	Designing pharmacoepidemiologic studies from clinical questions Instructor: Yinghui Liu
09:00 - 10:30 (90 mins)	Principles of descriptive and analytic pharmacoepidemiologic study designs Instructor: Krishna Undela
10:30 - 11:00 (30 mins)	BREAK
11:00 - 12:30 (90 mins)	Principles of advanced pharmacoepidemiologic study designs Instructor: Yinghui Liu
12:30 - 13:30 (60 mins)	LUNCH on your own
13:30 - 14:00 (30 mins)	Structure of a non-database pharmacoepidemiologic study protocol Instructor: Yinghui Liu
14:00 - 15:00 (60 mins)	Protocol writing for a non-database pharmacoepidemiologic study: hands-on experience Instructors: Yinghui Liu and Krishna Undela
15:00 - 15:30 (30 mins)	BREAK
15:30 - 16:30 (60 mins)	Statistical analytic programming relevant to non-database pharmacoepidemiology Instructor: Krishna Undela
16:30 - 17:00 (30 mins)	Critical appraisal of a non-database pharmacoepidemiologic study article Instructors: Krishna Undela and Yinghui Liu
17:00	CLOSE

Educational Session Program

Friday 21 November 2025

TRACK C: ARTIFICIAL INTELLIGENCE TOOLS TO SUPPORT PHARMACOEPIDEMIOLOGY RESEARCH (Intermediate)(English)

Session coordinator:

Dr Joseph Edgar Blais, Assistant Professor, Department of Pharmacology and Pharmacy, The University of Hong Kong

Instructors:

Professor Qingpeng Zhang, Associate Professor HKU Musketeers Foundation Institute of Data Science and Department of Pharmacology and Pharmacy, The University of Hong Kong

Professor Emmanuel Chun-Ka Wong, Clinical Assistant Professor, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong

A/P Amy HY Chan, Associate Professor, School of Pharmacy, The University of Auckland

Dr Jay Gong, Lecturer in Clinical Pharmacy Practice, School of Pharmacy, The University of Auckland

Dr Deliang Yang, Post-doctoral fellow, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong

Mr Daniel Qi Sun, PhD Candidate, Department of Pharmacology and Pharmacy, The University of Hong Kong

Time	Topic
09:00 – 10:30 (90 mins)	Introduction to language models and applications in unstructured clinical data Instructors: Qingpeng Zhang and Emmanuel Chun-Ka Wong
10:30 – 10:55 (25 mins)	BREAK
11:00 – 12:30 (90 mins)	AI models for prediction problems in pharmacoepidemiology Instructor: Qingpeng Zhang
12:30 – 13:30 (60 mins)	LUNCH on your own
13:30 – 15:00 (90 mins)	Efficient coding of prediction models in R and Python Instructors: Deliang Yang (Python) and Daniel Qi Sun (R)
15:00 – 15:25 (25 mins)	BREAK
15:30 – 16:00 (30 mins)	Efficient coding of prediction models in R and Python (Continued) Instructors: Deliang Yang (Python) and Daniel Qi Sun (R)
16:00 – 17:00 (60 mins)	AI tools in publishing medication-related AI and digital health research (Panel style discussion with answers to participant questions) Instructors: Qingpeng Zhang, Amy HY Chan, Jay Gong
17:00	CLOSE

Educational Session Program

Friday 21 November 2025

TRACK D: ADVANCED PHARMACOEPIDEMIOLOGY (English)

Session coordinators:

Dr Joshua Kueiyu Lin, Associate Professor, Harvard Medical School

Hu Li MD PhD, Head of Epidemiology and RWE, Neurocrine Biosciences

Speakers:

Prof Benjamin Bates, Assistant Professor, Center for Pharmacoepideimology and Treatment Science, Rutgers University

Prof Soko Setoguchi, Professor of Medicine and Epidemiology, Rutgers Robert Wood Medical School and Rutgers School of Public Health

Mr Daniel Tsai, School of Pharmacy, National Cheng Kung University

Dr Kenneth Man, University College London, School of Pharmacy

Prof Yong Chen, Professor of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine

Prof Xin Sun, Director, Chinese Evidence Based Medicine Center, West China Hospital, Sichuan University

Xiang Zhang PhD, Head Medical Affairs and HTA Statistics/Co-Lead FORExcellence, CSL Behring

Time	Topic
09:00 – 10:30 (90 mins)	PE Core: Assessing the impact of unmeasured confounders for credible and reliable real-world evidence Speakers: Hu Li and Xiang Zhang
10:30 – 11:00 (30 mins)	BREAK
11:00 – 12:30 (90 mins)	Region-specific: Methods in Environmental PE Speakers: Prof Benjamin Bates and Prof Soko Setoguchi
12:30 – 13:30 (60 mins)	LUNCH on your own
13:30 – 15:00 (90 mins)	PE Core: TTE/CCW sequential trials Speakers: Dr Joshua Kueiyu Lin, Mr Daniel Tsai and Dr Kenneth Man
15:00 – 15:20 (20 mins)	BREAK
15:20 – 16:10 (50 mins)	PE Core: Expanding the Reach of Target Trial Emulations: Federated Learning, Negative Controls, and Causal AI in Pharmacoepidemiology Speaker: Prof Yong Chen
16:10 – 17:00 (50 mins)	Region-specific: Methods in traditional medicine Speaker: Prof Xin Sun
17:00	CLOSE

Conference Program

Friday 21 November 2025

Educational Session Program (optional, additional fee)

Venue: Cyberport, Cyberport 3, 100 Cyberport Road, Hong Kong

(PLEASE SEE INDIVIDUAL TRACK PROGRAMS FOR DETAILS)

Lunch is not included in the registration fee.

Cyberport Arcade has many food venues where delegates can purchase lunch.

08:00-17:00	Registration and Information Desk Open
08:30-17:00	TRACK A: DATABASE PHARMACOEPIDEMIOLOGY (INTRODUCTORY/INTERMEDIATE)
Room:	Cyberport, Function Room 1
08:30-17:00	TRACK B: NON-DATABASE PHARMACOEPIDEMIOLOGY (INTRODUCTORY/INTERMEDIATE)
Room:	Cyberport, Smart Living Lab 3
09:00-17:00	TRACK C: ARTIFICIAL INTELLIGENCE TOOLS TO SUPPORT PHARMACOEPIDEMIOLOGY RESEARCH
Room:	Cyberport, Function Room 2
09:00-17:00	TRACK D: ADVANCED PHARMACOEPIDEMIOLOGY
Room:	Cyberport, Training Theatre
13:00	ISPE BOARD MEETING
Room:	Cyberport, Smart Living Lab 2
17:30-19:00	WELCOME RECEPTION Venue: El Charro Mexican Cantina, The Arcade, Cyberport
19:00-21:00	STUDENT TRAM PARTY

Conference Program

Day 1 – Saturday 22 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

07:30-17:15	Registration and Information Desk Open
08:30-10:00	OPENING PLENARY
Room:	Lecture Theatre 1 & 2
08:30-09:00	Conference Opening and Welcome Addresses Ursula Kirchmayer , ISPE President Esther W.Y. Chan , Local Host Committee Chair & Conference Co-Chair; The University of Hong Kong Hiraku Kumamaru , ISC Chair & Conference Co-Chair; Yokohama City University Chak-Sing Lau BBS, JP – Vice-President & Pro-Vice-Chancellor (Health), Dean of Medicine, The University of Hong Kong MC: Vincent Yan, President of the ISPE Student Chapter (Hong Kong) MC: Eunice Deng, Vice-president of the ISPE Student Chapter (Hong Kong)
09:00-10:00	Keynote Presentation 100. Digital tools for decentralized trials and digital endpoints Amy Chan, School of Pharmacy, The University of Auckland
10:00-10:40	MORNING BREAK / EXHIBITION / POSTER VIEWING

Conference Program

Day 1 – Saturday 22 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

10:45-12:15	CONCURRENT SYMPOSIA	
Room:	Lecture Theatre 1	Lecture Theatre 2
	Session 1: China mainland real world data landscape today and tomorrow Moderators: Kinwei Arnold Chan, Senior Vice President, TriNetX, LLC Joe Blais, The University of Hong Kong Speakers: Zhenna Huang, Center for Observational Research, Amgen Jifang Zhou, China Pharmaceutical University Pei Gao, Peking University Huiyao Huang, Cancer Hospital of Chinese Academy of Medical Science, National Cancer of China	Session 2: AI/ML applications in pharmacoepidemiology: Risk identification and management in Asian populations Moderators: Rui She, The Hong Kong Polytechnic University Aimin Yang, The Chinese University of Hong Kong Speakers: Aimin Yang, The Chinese University of Hong Kong Wai Kit Ming, City University of Hong Kong Shanquan Chen, London School of Hygiene & Tropical Medicine Sha Feng, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences Da Feng, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences Fan Jiang, Shandong University Yuanxuan Cai, Huazhong University of Science and Technology
12:15-13:35	LUNCH	
12:30-13:25	SPOTLIGHT POSTER SESSION 1 (PLEASE SEE SPOTLIGHT POSTER PROGRAM FOR DETAILS) Group 1 – Cardiometabolic medicines and diabetes research Room: 3 Sassoon Road, 1/F Learning Commons B Group 2 – Validation, drug utilization and outcome studies Room: 5 Sassoon Road, G/F SR1A	

Conference Program

Day 1 – Saturday 22 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

13:40-15:15	CONCURRENT CONTRIBUTED PAPERS	
Room:	Lecture Theatre 1	Lecture Theatre 2
	Session 1: Pharmacovigilance and medication safety: Carditis, deprescribing in elderly and medical devices	Session 2: Artificial intelligence and methods in pharmacoepidemiology
	Moderators: Masato Takeuchi , Shizuoka Graduate University of Public Health Shilpa Palaksha , JSS College of Pharmacy	Moderators: Olaf Klungel , Utrecht University Hu Li , Neurocrine Biosciences
13:45-14:00	101. Top 10 drugs most frequently associated with myocarditis and pericarditis adverse events Hyesu Jo, Kyung Hee University	107. Using routine clinical data to identify high-risk prediabetes for diabetes and cardiovascular-complications Aimin Yang, Chinese University of Hong Kong
14:00-14:15	102. Short-term risk of urinary retention following recent elevations in anticholinergic burden Daniel Tsai, National Cheng Kung University	108. Target trial emulation in oncology: Current use and future directions Huiyao Huang, Cancer Hospital of Chinese Academy of Medical Science, National Cancer of China
14:15-14:30	103. Patient satisfaction and adverse reactions to isotretinoin in acne patients Sunita Kularia, Parul University	109. Individualized treatment effect estimation in bipolar disorder: A causal machine learning approach Junhyuk Chang, Ajou University Graduate School of Medicine
14:30-14:45	104. Non-invasive imaging of facial erythema treated with a transdermal delivery system Wiktoria Odrzywołek, Medical University of Silesia	110. Methodological comparison of creatinine clearance calculation in chronic kidney disease Gayatri Panicker, Manipal College of Pharmaceutical Sciences
14:45-15:00	105. Development and validation of causality assessment tool for adverse-events to medical devices Adusumilli Pramod Kumar, Ramaiah University of Applied Sciences	111. Transcriptomic and pharmacogenomic analysis reveals biomarker-guided drug repositioning opportunities in DKD Nadyatul Husna, Reksodiwiry Military Hospital Padang
15:00-15:15	106. Barriers to adverse-event reporting of dental devices: A cross-sectional survey in India Jeesa George, M S Ramaiah University of Applied Sciences	112. Quasiquantitative bias analysis of comparator choice for Denosumab in KAERS database Suvin Park, Ewha Womans University
15:15-15:55	AFTERNOON BREAK /EXHIBITION / POSTER VIEWING	

Conference Program

Day 1 – Saturday 22 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

16:00-17:30	CONCURRENT SYMPOSIA	
Room:	Lecture Theatre 1	Lecture Theatre 2
	Session 3: Real World Oncology Data in the Asia-Pacific: Comparisons and Collaborations for Pharmacoepidemiologists Moderators: Benjamin Daniels, University of New South Wales Sydney Krishna Undela, National Institute of Pharmaceutical Education and Research (NIPER) Speakers: Benjamin Bates, Rutgers University Wei Kang, Tianjin University Shuei He Yang, National Cheng Kung University Ju Hwan Kim, Sungkyunkwan University Hiraku Kumamaru, Yokohama City University	Session 4: Data Environment in Asia and Multi-National RCT-DUPLICATE Project: Challenge, Insights and Value Moderators: Kenneth Man, University College London In-Sun Oh, Sungkyunkwan University Speakers: Francisco Lai, The University of Hong Kong Hwa Yeon Ko, Sungkyunkwan University Brian Meng Hsun Li, National Cheng Kung University Jenni Ilomaki, Monash University
17:30	END OF DAY 1	
18:30-21:30	GALA DINNER Venue: Ming Pavilion, Senior Common Room, 14/F, KK Leung Building, The University of Hong Kong MC: Vincent Yan, President of the ISPE Student Chapter (Hong Kong) MC: Eunice Deng, Vice-president of the ISPE Student Chapter (Hong Kong) Performance by The University Philharmonic Orchestra, Cultural Association, The University of Hong Kong	

Conference Program

Day 2 – Sunday 23 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

07:30-16:00	Registration and Information Desk Open	
08:00-08:50	AsPEN Showcase	
Room:	Lecture Theatre 2	
08:55-10:30	Moderators: Hiraku Kumamaru, Yokohama City University and Ju-Young Shin, Sungkyunkwan University Part 1: Introduction to AsPEN – Ju-Young Shin, Sungkyunkwan University Part 2: Current Achievements of AsPEN – Daniel Tsai, National Cheng Kung University Part 3: Future Directions of AsPEN – Kenneth Man, University College London	
	CONCURRENT CONTRIBUTED PAPERS	
	Lecture Theatre 1	Lecture Theatre 2
	Session 3: Vaccines and infectious diseases	Session 4: Pharmacoepidemiology at the macro level: Drug utilisation, policy impacts and global pharmacogenetics
	Moderators: Simon Bell , Monash University Hisashi Urushihara , Keio University	Moderators: Christopher T Rentsch , London School of Hygiene & Tropical Medicine Hei Hang Edmund Yiu , The University of Hong Kong
	09:00-09:15 RISING STAR AWARDEE 200. Cardiovascular effects of influenza vaccination: Target trial emulation using proximal causal inference Jinxin Guo, Peking University	206. Real-world treatment patterns and outcomes of biologics in severe asthma in Taiwan Hung-Wei Lin, IQVIA Solutions
	09:15-09:30 201. Safety of 23-valent pneumococcal polysaccharide vaccine in older adults: The VENUS Study Shiori Nishimura, Yokohama City University	207. Assessing ENDS impact on COPD: A systematic review and meta-analysis Ajay Malvi, National Institute of Pharmaceutical Education and Research
	09:30-09:45 202. Association between antibiotic use for non-gastrointestinal infections and inflammatory bowel disease flare-ups Yin Zhang, The University of Hong Kong	208. Nationwide serial cross-sectional study for outpatient cancer chemotherapy after new policy implementation Takehiro Ishida, Teikyo University
	09:45-10:00 203. Autoimmune disease risk after COVID-19 vaccination: A self-controlled case series Kevin Yi-Chen Liao, National Cheng Kung University	209. Impact of gender-affirming hormonal therapy on medication use: Interrupted time series analysis Sam Wade, Monash University
	10:00-10:15 204. Short-, medium- and long-term sequelae following COVID-19 infection: A multi-national cohort study Ran Zhang, The University of Hong Kong	210. Impacts of dedicated budget policy on long-acting injectable antipsychotic usage in Taiwan Grace Hui-Min Wu, Global Epidemiology, Johnson & Johnson
10:15-10:30	205. Long-Term effects and quality of life: COVID-19 versus vaccination over one year Yogendra Shrestha, Parul University	211. A multi-tier regressive markup pricing model for imported medicines in Sri Lanka Kalpani Aleththuge, University of Moratuwa

Conference Program

Day 2 – Sunday 23 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

10:30 – 11:10	MORNING BREAK / EXHIBITION / POSTER VIEWING	
11:15-12:45	CONCURRENT CONTRIBUTED PAPERS	
Rooms:	Lecture Theatre 1	Lecture Theatre 2
	Session 5: Evidence generation using multi-jurisdictional real-world data throughout the drug life cycle Moderators: Simon Bell , Monash University Siyan Zhan , Peking University Speakers: Celine Chui , The University of Hong Kong Ching-Lung Cheung , The University of Hong Kong Hong Bin , Sungkyunkwan University Zanfina Ademi , Monash University George Tan , Monash University Olaf Klungel , Utrecht University	Session 6: Harmonizing Post-Marketing Safety Evaluation Using RWD Across Regions Moderators: Yongjing Zhang , Office of the Chief Medical Officer, Johnson & Johnson Suzu Chia-Hsien Chang , Center for Observational Research, Amgen Speakers: Nakajo Ko , Office of the Chief Medical Officer, Johnson & Johnson Ju-Young Shin , Sungkyunkwan University Jeff Lange , Center for Observational Research, Amgen Marie De Bruin , Utrecht University
12:45-14:10	LUNCH	
13:00-13:55	POSTER SPOTLIGHT SESSION 2 (PLEASE SEE SPOTLIGHT POSTER PROGRAM FOR DETAILS) Group 1 – Research applying advanced methods in pharmacoepidemiology Room: 3 Sassoon Road, 1/F Learning Commons B Group 2 – Safety, implementation, and health system research Room: 5 Sassoon Road, G/F SR1A	



**ISPE'S 18TH ASIAN CONFERENCE
ON PHARMACOEPIDEMIOLOGY**

30 OCT - 1 NOV 2026

MELBOURNE, AUSTRALIA



Conference Program

Day 2 – Sunday 23 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

14:10-15:45	CONCURRENT CONTRIBUTED PAPERS	
	Lecture Theatre 1	Lecture Theatre 2
	Session 5: Cardiometabolic pharmacoepidemiology	Session 6: Central nervous system pharmacoepidemiology
	Moderators: Shan Luo , The University of Hong Kong Yusuke Okada , Keio University	Moderators: Kiyoshi Kubota , NPO Drug Safety Research Unit Jenny Ilomaki , Monash University
14:15-14:30	212. Effect of SGLT2i treatment durations on cardiovascular outcomes: target trial emulation study Bin Hong, Sungkyunkwan University	218. Aspirin in pregnancy and risk of atopic and neurodevelopmental disorders in offspring Brian Meng Hsun Li, National Cheng Kung University
14:30-14:45	213. Optimal INR target for atrial fibrillation patients with and without mitral stenosis Yu Yang, The University of Hong Kong	219. Utilization of methylphenidate and atomoxetine among children and adolescents in South Korea Kim Seonghae, Chungnam National University
14:45-15:00	214. Prescribing patterns and effectiveness of PCSK9 inhibitors in Hong Kong Bingbing Zhu, The University of Hong Kong	RISING STAR AWARDEE 220. Outcomes related to persistent opioid use after surgery or trauma Jiayi Gong, University of Auckland
15:00-15:15	215. Kidney outcomes of Dapagliflozin-10mg versus Empagliflozin-10mg versus Empagliflozin-25mg: Propensity-matched cohort study Johnny Cheung, The Chinese University of Hong Kong; Prince of Wales Hospital	221. Association between gabapentinoid and risk of traumatic fracture a multinational observation study Siu Chung Andrew Yuen, University College London
15:15-15:30	216. Risk of asthma exacerbation among users of novel antidiabetic agents: Target-trial emulation Avery Shuei-He Yang, Population Health Data Center	222. Comparing fracture risks following aripiprazole versus other prolactin-sparing antipsychotics after prolactin-increasing antipsychotics Wenxin Tian, The University of Hong Kong
15:30-15:45	217. Association of pioglitazone and risk of epilepsy using the US Collaborative Network Albert Tzu-Ming Chuang, Population Health Data Center	223. Economic evaluation of antidepressants in China: Development of a meta-model Liming Zhao, China Pharmaceutical University
15:45-16:25	AFTERNOON BREAK / EXHIBITION / POSTER VIEWING	

Conference Program

Day 2 – Sunday 23 November 2025

Venue: The University of Hong Kong, Lecture Theatre 1 & 2, 1/F, 3 Sassoon Road, Pokfulam

16:30-17:45	CLOSING PLENARY
Room:	Lecture Theatre 2
16:30-17:30	Keynote Presentation 224. From data to decisions: How real-world evidence transforms healthcare policy and practice Mary Beth Ritchey, Med Tech Epi, LLC; ISPE Immediate Past-President
17:30-17:45	Awards Presentations and Conference Close
17:45	END OF CONFERENCE

CREATING POSSIBLE

**We are committed
to a better,
healthier world for
everyone.**



HK-UNB-0414 v1.0 9-Nov-2025



For more information, please visit: <https://www.gilead.com/>

Poster Summary

Location	Saturday	Sunday
3 Sassoon Road, 1/F	Artificial Intelligence Genetics Mental disorders	Environmental Pharmacoepidemiology Pregnancy and Lactation Renal
3 Sassoon Road, 2/F	Diabetes	Medication Adherence / Pharmacy Practice
3 Sassoon Road, 3/F	Central Nervous System Pediatric Pharmacoepidemiology	Health Economics / Health Equity Pharmacovigilance
5 Sassoon Road, G/F	Autoimmune diseases / Allergies Cancer Cardiovascular Geriatric Pharmacoepidemiology Methods	COVID-19 Infectious diseases Medical Devices Others Respiratory



善久達®

INVEGA HAFYERA®

paliperidone palmitate

extended-release
injectable suspension

A NEW HOPE

for your patients with the **FIRST & ONLY^{1,2}**

6-monthly Injectable Therapy for Schizophrenia³

92.5% ONE-YEAR Relapse Free Rate⁴

10 LESS INJECTIONS Each Year
vs 1-monthly dosing regimen^{3,5}

With NO NEW SAFETY Signals vs 3-monthly dosing regimen^{4,6*}

*INVEGA HAFYERA compared with INVEGA TRINZA™

References: 1. Johnson & Johnson U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate). First and Only Twice-Yearly Treatment for Adults with Schizophrenia. 2021. Available at: <https://www.jnj.com/media-center/press-releases/johnson-and-johnson-announces-us-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia>

2. Cornil CJ et al. AMA NetRx Open 2024 2024;7(7):42421455. 3. INVEGA HAFYERA® Hong Kong Package Insert. Please refer to the latest approved version indicated with abbreviated PI.

4. Najari D et al. Int J Neuropsychopharmacol 2022;25:206–251. 5. INVEGA SUSTENNA® Hong Kong Package Insert. Please refer to the latest approved version indicated with abbreviated PI.

6. INVEGA TRINZA® Hong Kong Package Insert. Please refer to the latest approved version indicated with abbreviated PI.

For Healthcare Professionals Use Only

Johnson & Johnson

Johnson & Johnson (Hong Kong) Ltd.
13/F, Tower 3, Grand Century Place, 191 Prince Edward Road West, Mong Kok, Hong Kong
Tel: 2736 1711, Fax: 2736 1926

Scan here for Abbreviated Prescribing Information



INVEGA SUSTENNA®
extended-release
oral tablets



INVEGA TRINZA®
injectable solution



INVEGA HAFYERA®
injectable suspension

© 2025 Johnson & Johnson

26

Spotlight Poster Program

Saturday 22 November 2025

Group 1		Location: 3 Sassoon Road, 1/F Learning Commons B
SP01	Investigating prevalence of oct genotypes and metformin pharmacokinetic variability among indian population Dhivya D, JSS College of Pharmacy	
SP02	SGLT2 inhibitors and GLP-1 receptor agonists for brain-related outcomes in MASLD population Chae Min Lee, Sungkyunkwan University	
SP03	Comparison of biguanides and SGLT2 inhibitors on cardio-cerebrovascular outcomes, complications, and costs Eiji Nakatani, Nagoya City University	
SP04	Impact of Liraglutide on childhood obesity: A population-based estimation Emma Shi, Burlingame High School	
SP05	Questionnaire development and validation to assess community pharmacists' medication therapy management practices Zuha Shyma, Manipal College of Pharmaceutical Science	
SP06	Detection and resolution of DRPs in Pediatric intensive care hospital Neelima Ganzi, Raghavendra Institute of Pharmaceutical Education and Research	
SP07	SGLT2 inhibitors and the risk of nephrolithiasis in Thai patients with diabetes Thitiya Lukkunaprasit, Rangsit University	

Group 2		Location: 5 Sassoon Road, G/F SR1A
SP08	Medication adherence to PCSK9 inhibitors in clinical practice: Systematic review and meta-analysis Joe Blais, The University of Hong Kong	
SP09	Lipid lowering therapy use in high-risk CV patients of VESALIUS-REAL: Hong Kong Wai Ki Cheung, The University of Hong Kong	
SP10	Regulatory patterns in FDA oncology withdrawals: Spotlight on FDORA enforcement Gyeyoung Choi, Ewha Womans University	
SP11	Evaluating institutional medication use safety-program in ambulatory settings for chronic disease management Ravindra P Choudhary, JSS College of Pharmacy	
SP12	Development of novel poison severity and mortality scale: Optimizing emergency clinical outcomes Sannidhi Prabhu, MS Ramaiah University of Applied Sciences	
SP13	Comparison of clinical practice guidelines for ADHD patients with comorbidities across countries Jiwon Kim, Ewha Womans University	
SP14	Validation of diagnostic coding for chronic kidney disease using Japanese hospital-based database Momiji Otani-Kono, Keio University Faculty of Pharmacy	

Spotlight Poster Program

Sunday 23 November 2025

Group 1		Location: 3 Sassoon Road, 1/F Learning Commons B
SP15	Effect of ARB on the development of chronic diabetic complications: TTE study Xiaowei Chen, Peking University	
SP16	A machine learning-based predictive model for assessing QTc prolongation in hospitalized patients Hsiu-Ting Chien, Harvard Medical School	
SP17	Depression in rheumatoid arthritis patients initiating JAKi versus TNFi: Target Trial Emulation Shin Yeong Kim, Jeonbuk National University	
SP18	Examining the necessity of subgroup-based Rapid Cycle Analysis: Lessons from COVID-19 vaccine Koshiro Arai, Japan Institute for Health Security	
SP19	Live zoster vaccination and chronic respiratory disease: An emulated target trial Kyeongmin Lee, Kyung Hee University	
SP20	Gallbladder cancer risk factors in northeast India: A mixed-methods sequential explanatory analysis Christy Thomas, National Institute of Pharmaceutical Education and Research	
SP21	Establishing sex-age-specific TSH and FT4 reference intervals among adults in Hong Kong Jiawen Lu, The Hong Kong Polytechnic University	

Group 2		Location: 5 Sassoon Road, G/F SR1A
SP22	Use of Surrogate endpoints and Real-world evidence in recent oncology NICE submissions Sojeong Bae, Ewha Womans University	
SP23	Effectiveness of academic detailing for type 2 diabetes care in Ontario, Canada Cherry Chu, Women's College Hospital	
SP24	Digital solutions in Materiovigilance for enhanced safe use of medical devices Gangadharappa HV, JSS College of Pharmacy	
SP25	Cardiovascular risk of romosozumab versus teriparatide: Cohort study using Japan's national database Hotaka Maruyama, Pharmaceuticals and Medical Devices Agency	
SP26	Potential interactions between SSRIs and DOACs: Population-based cohort and case-crossover study Marco Chau, London School of Hygiene & Tropical Medicine	
SP27	Clinical comparison of magnesium versus traditional bone implants in fracture fixation Lejin Mathew, Independent Researcher	
SP28	Study on prevalent CYP2C19 variants driven sertraline PopPk in South Indian patients Manojkumar V, JSS College of Pharmacy	

Poster Program

Saturday 22 November 2025

Artificial Intelligence		Location: 3 Sassoon Road, 1/F
P100	Comparing GBTA, HMMs, and process mining for medication use patterns Harvey Jia Wei Koh, Monash University	
P101	Validation of the P-CARDIAC: A risk model for cardiovascular events Celia Lin, The University of Hong Kong	
P102	Development and validation of 10-year cardiometabolic risk prediction models in prediabetic adults Jie Mei, The University of Hong Kong	
P103	Bayesian dosage adjustment of tacrolimus in kidney transplantation: A systematic review Tejashree Pasumarthi, Manipal College of Pharmaceutical Sciences	
P104	Improving UTI diagnosis using clinical symptoms and laboratory tests using machine learning Vismaya V, JSS College of Pharmacy	
P105	Predicting ischemic stroke risk in patients with atrial fibrillation with drug-protein-disease network Qingpeng Zhang, The University of Hong Kong	
P106	Unsupervised learning for novel cardiac surgery phenotyping via multimodal, high-dimensional perioperative data Jifang Zhou, Xiang Li, Ruijian Huang, China Pharmaceutical University	

Genetics		Location: 3 Sassoon Road, 1/F
P107	Identification of HLA alleles in Thailand using long-read sequencing for pharmacogenomics applications Maliheh Ershadian, Mahidol University; Ramathibodi Hospital	
P108	Genes, beliefs, and behavior: A factor-analytic study on pharmacogenomic acceptance in depression Shyam Nikethen Girivasan, JSS College of Pharmacy	
P109	Genome-wide association study of TKI-induced hepatotoxicity in all of us Tae Young Jung, Chungbuk National University	

Mental Disorders		Location: 3 Sassoon Road, 1/F
P111	Reduction of psychiatric hospitalization after revisions for Mental Health and Welfare Act Tomokazu Furukawa, Johnson & Johnson	
P112	Drug utilisation evaluation of antipsychotics at a tertiary care hospital Regila Rex, Government Medical College Suryapet	
P113	Has mental healthcare reached the grassroots? Evidence from psychotropic drug utilization Senlin Sha, Shandong University	

Poster Program

Saturday 22 November 2025

Diabetes		Location: 3 Sassoon Road, 2/F
P114	Vitamin D deficiency-related factors influence surgical management strategy in diabetic foot infection Ruby Benson, Manipal College of Pharmaceutical Sciences	
P115	Assessment of factors affecting self-management practices among type 2 diabetes mellitus patients Yamini Bhamare, MS Ramaiah University of Applied Sciences	
P116	Sacubitril/valsartan and SGLT2 inhibitors in HFREF with renal dysfunction: Time-dependent Cox's models Tung-Chun Russell Chien, National Taiwan University	
P117	Glucose monitoring effectiveness in non-insulin dependent T2DM patients: An umbrella review Nathaniel Foo, Monash University	
P118	Safety and efficacy of chiglitazar for treating T2D in China: A meta-analysis Xintong He, IQVIA	
P119	Hepatic effectiveness of empagliflozin versus dapagliflozin in metabolic dysfunction-associated steatotic liver disease Suyeon Kim, Sungkyunkwan University	
P120	Change in antihypertensive use after initiation of second-line oral antidiabetics in Korea Ye-Jee Kim, University of Ulsan	
P121	Synergistic association of RAAS inhibitors and SGLT2 inhibitors on major hepatic events Hwa Yeon Ko, Sungkyunkwan University	
P122	UTI risk & treatment outcomes with SGLT2 inhibitors in T2DM: Retrospective study Prasanna Kumar, Manipal College of Pharmaceutical Sciences	
P123	Weight loss effects of semaglutide in normal-weight adults: A meta-analysis of RCTs Dain Lee, Yonsei University	
P124	Effects of vitamin D supplementation in diabetes or prediabetes: An umbrella review Jianzhao Liu, Southern University of Science and Technology	
P125	Real-world impact of funding decisions on SGLT2i utilisation and prescribing in Singapore San Zeng Low, Agency for Care Effectiveness	
P126	Development, validation of KAP questionnaire for tuberculosis patients with type-II diabetes mellitus Pravachana Malakapogu, Manipal College of Pharmaceutical Sciences	
P127	Association between DPP-4 inhibitor use and Parkinson's disease risk in T2DM Jun Hyuk Park, Chungbuk National University	
P128	Oral antidiabetics impact on COPD exacerbations in type 2 diabetes: Network Meta-Analysis Jayaraj Patil, National Institute of Pharmaceutical Education and Research	
P129	Alcohol and drug abuse in patients with diabetes receiving GLP1 receptor agonists Daniel Tsai, National Cheng Kung University	
P130	Optimising renal function monitoring intervals for type 2 diabetes patients Boyuan Wang, The University of Hong Kong	
P131	Use of dipeptidyl peptidase-4 inhibitors and risk of acute pancreatitis: Trend-in-trend design Avery Shuei-He Yang, Population Health Data Center	
P132	Risk of diabetic retinopathy with GLP-1RA, SGLT2i, and DPP-4i: A real-world study Yongqi Zheng, Peking University	
P133	Re-admission and safety outcomes of leadless vs transvenous pacemakers Jifang Zhou, Xiang Li, Ruijian Huang, China Pharmaceutical University	

Poster Program

Saturday 22 November 2025

Central Nervous System		Location: 3 Sassoon Road, 3/F
P134	Optimizing refractory epilepsy treatment through structured seizure monitoring: A prospective cohort study Jatin Batra, JSS College of Pharmacy	
P135	Beliefs and experiences of opioid users in New Zealand: A cross-sectional study Jiayi Gong, University of Auckland	
P136	Changing GLD patterns in Australian: General vs neurodegenerative populations (2015–2024) Qingke He, Monash University	
P137	Comparing the risk of dementia and Parkinson’s disease between abiraterone and enzalutamide Jaehee Jung, Yonsei University	
P138	Dementia risk associated with blood-brain-barrier-crossing versus non-crossing angiotensin-converting enzyme inhibitors Jisu Park, Sungkyunkwan University	
P139	Anti-seizure drug-related problems in patients with refractory epilepsy Salome Vanlalduhaki, JSS College of Pharmacy	
P140	Prescription opioid dose change and risk of ED visits: A case-crossover study Ting Xia, Monash University	
P141	Trends in gabapentinoid prescriptions among opioid users for pain management in Malaysia Che Suraya Zin, International Islamic University Malaysia	

Pediatric Pharmacoepidemiology		Location: 3 Sassoon Road, 3/F
P142	Characteristics, determinants, and antibiotic usage associated with Gram-negative infections in pediatric patients Krishnakumar Athavil, Manipal College of Pharmaceutical Sciences	
P143	Outpatient antibiotic prescribing in early life: Analysis of Swiss health claims data Claudia Becker, University of Basel	
P144	Sex-specific reporting patterns of suicide-related adverse drug events in children and adolescents Haerin Cho, Ewha Womans University	
P145	Risk prediction models for adverse drug reactions in pediatric: A systematic review Ruonan Gao, Sichuan University	
P146	Association of dexamethasone prescription with acute kidney injury among hospitalized children Yuanhui Hu, Sichuan University	
P147	Sex-specific associations between habitual drug use and suicide-related behaviors in Korean adolescents Jeong Ah Kim, Ewha Womans University	
P148	Relative-age effect on ADHD diagnosis and pharmacologic treatment in children Andrew Li, University of British Columbia	
P149	Colistin monotherapy vs combination in pediatric MDR gram-negative infections: Propensity analysis Ajaree Rayanakorn, Chiang Mai University	
P150	Drug targets for attention deficit hyperactivity disorder: A proteomic-wide Mendelian randomization study Xingyu Shen, The University of Hong Kong	

Poster Program

Saturday 22 November 2025

Pediatric Pharmacoepidemiology

Location: 3 Sassoon Road, 3/F

P152	GLP-1 receptor agonists in children: A FAERS analysis of adverse events Aylin Vidin Sen, Bahçeşehir University
P153	Consumption patterns of ADHD medication in mainland China: 2015-2023 Yifei Zhao, Xi'an Jiaotong University
P154	Medication treatment patterns and persistence in chinese children and adolescents with ADHD Jifang Zhou, Xiang Li, Ruijian Huang, China Pharmaceutical University

Autoimmune Diseases / Allergies

Location: 5 Sassoon Road, G/F

P155	Applying hierarchical clustering of patient characteristics in Japanese patients with plaque psoriasis Chengxiang Du, Global Epidemiology, Johnson & Johnson
P156	Utilization patterns of advanced therapies in inflammatory bowel disease in South Korea Ju Hwan Kim, Sungkyunkwan University
P157	Clinical and healthcare burden of difficult-to-treat rheumatoid arthritis in Japan Wen Shi Lee, Institute of Science Tokyo
P158	Real-world persistence with Ustekinumab treatment for psoriasis in Japan and China Tong Li, Johnson & Johnson
P159	Temporal trends in biosimilar prescriptions in Japan Minako Matsumoto, Keio University
P160	Comparative efficacy between bepotastine and olopatadine for the treatment of allergic conjunctivitis Ajeesh Mohammed P Z, National Institute of Pharmaceutical Education and Research
P161	Establishing skin prick test concentrations for diagnosing immediate drug allergies Shilpa Palaksha, JSS College of Pharmacy
P162	Recognizing Warm Autoimmune Hemolytic Anemia: A study from 3 hospitals in China Meng Shu, Johnson & Johnson

Poster Program

Saturday 22 November 2025

Cancer		Location: 5 Sassoon Road, G/F
P163	The relationship between event-free and overall survival of head and neck carcinoma Philip Chun-Ming Au, The University of Hong Kong	
P164	Translating potential drug-drug interactions into clinically actionable insights in hematological malignancy patients Deepthi Avvaru, Kasturba Medical College	
P165	Population-based GWAS of immune checkpoint inhibitor-induced hepatotoxicity Seung Hwan Chang, Chungbuk National University	
P166	CAR T-cell therapy for acute myeloid leukemia: A systematic review and meta-analysis Bunchai Chongmelaxme, Chulalongkorn University	
P167	Hypomethylating agent versus venetoclax combination for Asian patients with Acute Myeloid Leukaemia Qiwen Fang, The University of Hong Kong	
P168	Efficacy and safety of first-line ICIs for advanced NSCLC: NMA of RCTs Rohan Jagdale, National Institute of Pharmaceutical Education and Research Guwahati	
P169	Patient-reported outcomes of pharmacist-led topical steroid use in breast cancer radiotherapy Sheba John, Sarada Vilas College of Pharmacy	
P170	Risk factor analysis for immediate hypersensitivity reactions in chemotherapy patients Sheba John, Sarada Vilas College of Pharmacy	
P171	Delayed withdrawal of boxed warning-labeled oncology drugs under accelerated approval Seonmin Lee, Ewha Womans University	
P172	Safety signals of concomitant immune checkpoint inhibitors and corticosteroids in VigiBase Hui-Eon Lee, Ewha Womans University	
P173	Colchicine use for gout and risk for cancer Yoonmin Jang, Sungkyunkwan University	
P174	Association between CDK4/6 inhibitors and risk of cardiotoxicity in breast cancer patients Hsin Lien, National Yang Ming Chiao Tung University	
P175	Immunosuppressant use among organ transplant patients: A single-center study in Vietnam Do Hoang Vy Nguyen, Ho Chi Minh City University of Medicine and Pharmacy	
P176	PD-L1 expression modulates frontline ALK-TKI response in ALK-rearranged NSCLC: Target trial emulation Yijin Qiu, Jinan University	
P177	Disease context matters: Real-world correlation between surrogate endpoints and survival in oncology Jaemin Sim, Ewha Womans University	
P178	Chemotherapy toxicity and intolerance assessed by CARG-TT scores in Chinese elders Lirong Yang, Renji Hospital; Shanghai Jiao Tong University	

Poster Program

Saturday 22 November 2025

Cardiovascular		Location: 5 Sassoon Road, G/F
P180	Habitual aspirin use and liver fat and inflammation: UK Biobank study Qi Feng, Imperial College London	
P181	Assessing volume-based procurement effects on lipid-lowering drugs in Jiangsu with mixed-effects model Yuanyuan Fu, The First Affiliated Hospital with Nanjing Medical University	
P182	Real-world evaluation of ticagrelor in acute coronary syndrome: A retrospective cohort study Louise Gek Huang Goh, Ministry of Health	
P183	Real-world effectiveness of PCSK9i in hyperlipidemia patients with different ASCVD risk Yuhuan Ko, Linkou Chang-Gung Memorial Hospital	
P184	Peripheral edema following the use of amlodipine and celecoxib: A case-crossover study Kiyoshi Kubota, NPO Drug Safety Research Unit	
P185	Effect of PCSK9 inhibitors on major adverse cardiovascular events in patients with atherosclerotic cardiovascular disease: A population-based study using target trial emulation Lijia Liu, Peking University	
P186	Heterogeneity in statin efficacy for primary cardiovascular prevention: A meta-analysis Yujun Long, Shenzhen University of Advanced Technology	
P187	Apolipoprotein A-I does not associate with cardiovascular outcomes at any LDL-cholesterol Yujie Ai, The University of Hong Kong	
P188	Association of dietary and circulating micronutrients with NAFLD: Meta-analysis of observational studies Mamidi Niveditha, National Institute of Pharmaceutical Education and Research	
P189	Effectiveness of sodium intake among athletes: A comprehensive systematic review Jaseela Nk, National Institute of Pharmaceutical Education and Research	
P190	Statin and risk of amyotrophic lateral sclerosis: An active-comparator, new-user cohort study Yusuke Okada, Keio University	
P191	Factors associated with improved patient reported outcomes in coronary artery disease Kavya A V, M S Ramaiah University of Applied Sciences	
P192	Effect of concomitant use of statins and direct oral anticoagulants Qiuyan Yu, The University of Hong Kong	

Poster Program

Saturday 22 November 2025

Geriatric Pharmacoepidemiology		Location: 5 Sassoon Road, G/F
P193	Evaluating the impact of anticholinergic burden on fall and fracture Albert Tzu-Ming Chuang, Population Health Data Center	
P194	Diabetes-medication use and dementia at end-of-life in the United Kingdom and Australia. Darshna Goordeen, Monash University	
P195	Serial cross-sectional analysis for nationwide polypharmacy reduction after policy implementation during COVID-19 Takehiro Ishida, Teikyo University Graduate School of Public Health	
P197	Clusters of psychotropic and health service use in Australians living with dementia Edward Chun Yin Lau, The University of Sydney	
P198	Antipsychotics and risk of falls/fractures in dementia: A systematic review and meta-analysis Pajaree Mongkhon, University of Phayao	
P199	Feasibility study on polypharmacy using a deprescribing payment scheme in Japan Masato Takeuchi, Shizuoka Graduate University of Public Health	
P200	Marijuana use accelerates biological aging among adults: Mediating role of blood cadmium Kai Wei, Guizhou Provincial People's Hospital	
P201	Statin therapy for primary prevention in older patients with chronic kidney disease Wanchun Xu, The University of Hong Kong	
P202	Polypharmacy, influencing factors, and adverse outcomes in elderly patients with heart failure Jifang Zhou, Xiang Li, Ruijian Huang, China Pharmaceutical University	

Methods		Location: 5 Sassoon Road, G/F
P203	Evaluating comparability using negative control outcomes in osteoporosis Kevin Yi-Chen Liao, National Cheng Kung University	
P204	Real-world evidence in drug approval and medical affairs: Integration and industry insights Yu Shi, AstraZeneca	
P205	Data transportability as an underutilised method to bridge evidence gaps in Asia Yan Ran Wee, Costello Medical Singapore Pte Ltd	
P206	Enhancing RWE reliability: Data source selection in China Wenyan Zhao, AstraZeneca	
P207	Methodological considerations of knowledge-based surveys in evaluating effectiveness of risk minimization measures Lynn Zhou, Sanofi	

Poster Program

Sunday 23 November 2025

Pregnancy and Lactation		Location: 3 Sassoon Road, 1/F
P300	Comprehensive evaluation of maternal drug exposures and offspring autism: From nationwide database Takanori Yanai, Kyoto University	
P301	Safety of early pregnancy use of GLP-1 receptor agonists and SGLT-2 inhibitors Jifang Zhou, Xiang Li, Ruijian Huang, China Pharmaceutical University	
P302	Safety of medications prescribed during pregnancy for birth outcomes: An umbrella review Xuanqi Cui, University of Macau	
P303	Establishment of algorithms for identifying potential immune-mediated diseases and pregnancy outcomes Yang Feng, Xiamen Chazen Biomedical Technology Co., Ltd	
P304	Refining GA estimation in claims-based pregnancy algorithms in Korea Hee-Jin Kim, Ewha Womans University	
P305	First-trimester exposure to specified antifungal medications and major congenital malformations in infants Tadaharu Kunitoki, Tohoku University	
P306	Insulin glargine for gestational diabetes is associated with macrosomia compared with detemir Yubin Lee, Sungkyunkwan University	
P307	Does treating genital herpes infection during pregnancy reduce placenta previa? Dekun Li, Kaiser Foundation Research Institute	

Environmental Pharmacoepidemiology		Location: 3 Sassoon Road, 1/F
P308	Impacts of extreme temperature events on intraoperative hypotension: A multicenter cohort study Ruijian Huang, China Pharmaceutical University	
P309	Modeling seasonality and ambient temperature-humidity interaction effects on macrolide use patterns Tanavij Pannoi, Walailak University	

Renal		Location: 3 Sassoon Road, 1/F
P310	Gastric acid suppressants and peritonitis in peritoneal dialysis: A target trial emulation Franco WT Cheng, Min Fan, The University of Hong Kong	
P311	Lithium discontinuation lowers chronic kidney disease risk: UK case-control study Rachel Yui Ki Chu, The University of Hong Kong	
P312	Stroke risk for peritoneal dialysis patients on oral anticoagulants: A sequential TTE Min Fan, The University of Hong Kong	
P313	Prevalence and risk-factors of CKDu in Udupi district, Karnataka: Cross-sectional follow-up study Asha K Rajan, Manipal College of Pharmaceutical Sciences	
P314	Nationwide expansion of home dialysis after new policies in 2022 and 2023 Mirai Sakaki, Glocal Innovator & Future Talent Society	

Poster Program

Sunday 23 November 2025

Medication Adherence / Pharmacy Practice

Location: 3 Sassoon Road, 2/F

P315	Assessment of clinical pharmacist intervention on drug-related problems in neurological patients Suhani A, JSS College of Pharmacy
P316	Impact of medication information exposure on adherence to antihypertensive medication Sofa D Alfian, Universitas Padjadjaran
P317	A study on drug-related problems in critical care patients receiving antimicrobial agents Binsu Binu, JSS College of Pharmacy
P318	Translation and validation of the Pharmacy Services Questionnaire in a Chinese population Chi Lam Cheung, The University of Hong Kong
P319	Raising awareness: The role of health education in breast cancer prevention among women Apoorva Dev.M, Rajiv Gandhi University of Health Sciences
P320	Pharmacist-led education in acute coronary syndrome: Systematic review and meta-analysis Caroline Trin, Monash University
P321	Reliability and harmonisation of DDI checkers for chronic disease: A scoping review Brayden Gibson, Monash University
P322	The impact of telemedicine use on adherence to antihypertensive in elderly Indonesians Wardatul Jannah, Universitas Padjadjaran
P323	Assessment of factors affecting self-management among type 2 diabetics: Tertiary hospital study Ajoshson John, MS Ramaiah University of Applied Sciences
P324	Enhancing informed decision-making in gender-affirming care through patient-centered education on hormonal therapies Sheba John, Sarada Vilas College of Pharmacy
P325	Pharmacy-based predictors of non-adherence and non-persistence in patients with multimorbidity Qisty A Khoiry, Universitas Padjadjaran
P326	Assessment of drug-related problems in prescriptions arriving to community pharmacy Vijayanarayana Kunhikatta, Manipal College of Pharmaceutical Sciences
P327	Development and validation of Self-Administration Medication Error (SAME) tool Anusha Natarajan, Jawaharlal Institute of Postgraduate Medical Education and Research Puducherry
P328	Guideline-directed medical therapy adherence in heart failure management: Real-world data from India Aashi Rajput, M. S. Ramaiah University of Applied Sciences
P329	Assessment of patient perceptions towards chronic diseases and medication adherence Alan Saji, JSS College of Pharmacy
P330	Assessing the effect of pharmacist-led education on medication adherence in HIV-positive patients Balaji Sathyanarayana Gupta, JSS College of Pharmacy
P331	Effect of home-based educational visits on antibiotic use among Sri Lankan mothers Fathima Samha Shiraz, Kotelawala Defence University

Poster Program

Sunday 23 November 2025

Medication Adherence / Pharmacy Practice

Location: 3 Sassoon Road, 2/F

P332	Mobile Diary as a tool for patient-centered rare disease management Kong Chian Toh, IQVIA Solutions Asia Pte Ltd
P333	Barriers and enablers to cardiovascular medication adherence: A qualitative evidence synthesis Caroline Trin, Monash University
P334	Stewardship of medication errors in a developing country's scenario: Clinical pharmacist's role Madhugiri Prakash Venkatesh, JSS College of Pharmacy
P335	Improving comprehension of OTC drug instructions through visualization Yu Yang, Peking University

Health Economics / Health Equity

Location: 3 Sassoon Road, 3/F

P336	Trends in the utilization, expenditure, and costs of non-insulin glucose-lowering drugs Rawan Almadfaa, King Abdulaziz University
P337	Clinical and cost-effectiveness of NSTEMI management with kidney-impairment during the COVID-19 pandemic Patrick Bidulka, London School of Hygiene & Tropical Medicine
P338	Prices and affordability of essential medicines in Sri Lanka after economic crisis Thisara Gallage, General Sir John Kotelawala Defence University
P339	Investigating health insurance disparities and their impact on medicine access Chethana Hosamalangi Suresha, JSS College of Pharmacy
P340	Improved access without savings: Real-world impact of trastuzumab biosimilar in South Korea Minji Kim, Ewha Womans University
P341	Effect of educational intervention on caregivers to improve malnutrition in tribal children Sowmya Pujari, Manipal College of Pharmaceutical Sciences
P342	Public health and pharmaceutical equity: Availability of essential medicines in public hospitals Kampelly Srikanth, Government Medical College
P343	Cost-effectiveness analysis of statins, berberine, and combination for cardiovascular disease primary prevention Jie Jane Zhao, The University of Hong Kong

Poster Program

Sunday 23 November 2025

Pharmacovigilance		Location: 3 Sassoon Road, 3/F
P344	Inclisiran-linked adverse event detection using FAERS disproportionality metrics: Exploratory study Nandana A, M.S. Ramaiah University of Applied Sciences	
P345	Development of drug safety information in Korea: Lidocaine (injection) and anaphylactic reactions Eunmi Choi, Korea Institute of Drug Safety & Risk Management	
P346	Overview of patient-reported outcome measures in post-marketing surveillance across Asia Pacific Zhen Dong, IQVIA	
P347	Association between proton pump inhibitors and gout risk in a cohort study Jinyeon Gil, Chungbuk National University	
P348	Age-specific signals for duloxetine using the Korea Adverse Event Reporting System Database Jimin Hwang, Chungnam University	
P349	Evaluating post-marketing regulatory impact on hypocalcemia safety signals of Denosumab in VigiBase Young-Hyo Jeon, Ewha Womans University	
P350	Subgroup disproportionality analysis of methylphenidate adverse events in VigiBase and KAERS database Na-Young Jeong, Ewha Womans University	
P351	FAERS flags nebivolol induced melaena: A newly identified adverse event Purnima Kumari, M.S. Ramaiah University of Applied Sciences	
P352	Real world data of drug induced cerebral hemorrhage: Disproportionality analysis using FAERS Litty Kunjumon, Independent Researcher	
P353	FAERS signal detection of tirzepatide adverse events via disproportionality evaluation Hemappriya Murugan, M.S. Ramaiah University of Applied Sciences	
P354	Unravelling drug-safety: Blockchain-powered Pan-Asian Network - decentralised pharmacovigilance, real-time adverse event insights Gokula vasa Nagarajan, Sri Ramakrishna Institute of Paramedical Sciences	
P355	Association between hair loss medications and psychiatric AEs: A dual-source pharmacovigilance review Fangyi Qian, Fudan University	
P356	Disproportionality analysis of Methotrexate using the FDA adverse event reporting system database Albin T Thottankara, Manipal College of Pharmaceutical Sciences	
P357	Ferric Carboxymaltose-induced serious adverse events: Disproportionality analysis and systematic review Krishna Undela, National Institute of Pharmaceutical Education and Research	

Poster Program

Sunday 23 November 2025

COVID-19		Location: 5 Sassoon Road, G/F
P358	COVID-19 vaccines and mortality risk: Comparison of estimates from self-controlled case series Norazida Ab Rahman, Institute for Clinical Research, Ministry of Health Malaysia	
P359	Psychiatric and neuropsychiatric sequelae of COVID-19 within 2 years: A multinational study Yi Chai, Shenzhen University	
P360	Association of penicillin allergy label with post-COVID-19 condition and subsequent clinical outcomes Ubbonphan Chaichana, University College London	
P361	Patterns of persistent healthcare use among people with long COVID Naveed Janjua, University of British Columbia	
P362	Long-term risk of dementia following COVID-19: A retrospective cohort study in Korea Na-Young Jeong, Ewha Womans University	
P363	Inpatient antibiotic utilization before and during COVID-19 in an Indonesian hospital Erna Kristin, Universitas Gadjah Mada	
P364	Multi-organ involvement of clinical sequelae following COVID-19 infection: A multinational cohort study Ivan Lam, The University of Oxford	
P365	Trends in influenza vaccine uptake before and during the COVID-19 pandemic Jialing Lin, University of New South Wales	
P366	Risk of Type 1 diabetes and mRNA-based COVID-19 vaccines in young adults Daniel Tsai, National Cheng Kung University	
P367	Impact of COVID-19 restrictions on estimating causal effects: Fluoroquinolones and tendon rupture. Angel Wong, London School of Hygiene and Tropical Medicine	
P368	Nationwide serial cross-sectional study for antimicrobial drug usage during COVID-19 pandemic Satoshi Yamaguchi, Glocal Innovator and Future Talents Society (Gifts))	

Poster Program

Sunday 23 November 2025

Infectious Diseases		Location: 5 Sassoon Road, G/F
P369	Study of utilization and evaluation pattern of antimicrobials in critical care units Sandra Elsa Biju, JSS College of Pharmacy	
P370	Performance of electronic algorithms for dengue and severe dengue detection Sze Ling Chan, SingHealth	
P371	Rifampicin for hypervirulent <i>Klebsiella pneumoniae</i> infections: A systematic review Nagendra Babu Danavath, Manipal Academy of Higher Education	
P372	Pharmacist vital allies in pediatric care: Evaluating KAP of immunization in public Fathima Hiba, Al Shifa College of Pharmacy	
P373	Aseptic meningitis induced by antibiotics: A disproportionality analysis Mohammed Salim Karattuthodi, Manipal College of Pharmaceutical Sciences	
P374	Incidence trend for extended Carbapenem-Resistant Enterobacteriaceae colonisation: An Interrupted time series analysis Chi Him Lau, The University of Hong Kong	
P375	Understanding inpatient antibiotic prescribing: A synthesis of evidence on determinants and interventions Sinan Ma, Xi'an Jiaotong University	
P376	Probiotic supplementation improves ATT-related safety in tuberculosis patients: A prospective cohort study Sonal Sekhar Miraj, Manipal College of Pharmaceutical Sciences	
P377	Evaluation of antibiotic prescription in community pharmacy based on WHO AWaRe classification Sreedharan Nair, Manipal College of Pharmaceutical Sciences	
P378	Evaluating illness severity and prescribing trends in paediatric respiratory tract infections Elsa Paulson, National Institute of Pharmaceutical Education and Research	
P379	Economic outcomes of consumption and resistance of restricted antibiotics in a hospital Imelda Peña, University of the Philippines	
P380	Evaluating the ADR-associated hospitalisation burden in PLHIV: 72-week prospective cohort study Basavaraj Poojar, Manipal University College	
P381	Prevalence, clinical profile, and outcomes of low-level viremia among HIV-1 adults Arunima Prakash, JSS College of Pharmacy	
P382	Characteristics and safety of RSV vaccines based on the US VAERS data Jingjing Qian, Auburn University	
P383	No excess risk of mortality or multimorbidity following hemorrhagic stroke after mRNA-vaccination Song Song, The University of Hong Kong	
P384	Assessing Point-of-Care Testing accuracy for differentiating Gram-Negative/Gram-Positive infections: A combined quantitative analysis Yan Wang, The Second Affiliated Hospital of Xi'an Jiaotong University	
P385	Antibiotic resistance patterns and predictors of limb loss in diabetic foot infections Shaniya Wilson, NGSM Institute of Pharmaceutical Sciences	
P386	Characterization of disease burden associated with bacterial bloodstream infections, Hong Kong, 2012–2021 Guanhao Zheng, The University of Hong Kong	

Poster Program

Sunday 23 November 2025

Medical Devices

Location: 5 Sassoon Road, G/F

P387	Tertiary healthcare-based study on QoL and dialysis events using dialysate analysis Lubaba Ashraf, Alshifa College of Pharmacy
P388	Materiovigilance integrating into clinical curriculum-observational study of medical device adverse events Dilip Chandraseker, Alshifa College of Pharmacy
P389	Flatline warnings: Materiovigilance of implantable pacemaker pulse generator events via MAUDE database Jeesa George, M S Ramaiah University of Applied Sciences
P390	Clinical risk assessment and standardization of dental device use: A materiovigilance initiative Jeesa George, M S Ramaiah University of Applied Sciences
P391	Evaluating device-related adverse events in tracheal tubes: A materiovigilance-based MAUDE study Jeesa George, M S Ramaiah University of Applied Sciences
P392	Approval process of high-risk medical devices in India, USA, Europe and Australia Natesh Gunturu, JSS Academy of Higher Education and Research
P393	Adverse event trends in cochlear implants: An analysis from the MAUDE database Crispin Dona J, MS Ramaiah University of Applied Sciences
P394	Adverse events associated with spinal fusion implants: A 10-Year MAUDE-based analysis Jeesa George, MS Ramaiah University of Applied Sciences
P395	A MAUDE- based analysis of adverse-events associated with transcatheter aortic valve device Hari R.S, MS Ramaiah University of Applied Sciences
P396	Integrating epidemiologic methods to evaluate safety and regulatory gaps of neuro-devices Baviya Priyadharshini Rajkumar, JSS College of Pharmacy
P397	Medical device adverse events in geriatric ICU: A cross-sectional materiovigilance study Deeksha S, MS Ramaiah University of Applied Sciences
P398	Medical device vigilance in pulmonology and ICUs: A prospective observational study Binsha Zakkir, Al Shifa College of Pharmacy

Respiratory

Location: 5 Sassoon Road, G/F

P399	Medication patterns among COPD acute exacerbation inpatients: impact of comorbid cardiovascular diseases Haifan Bai, Fudan University
P400	Association between leukotriene receptor antagonist use and the risk of dementia Boqing Chen, University College London
P401	Respiratory risks associated with P-CAB versus PPI among COPD patients Soobeen Park, Jeonbuk National University

Poster Program

Sunday 23 November 2025

Others		Location: 5 Sassoon Road, G/F
P402	Patterns of disease prevalence and multimorbidity using Real-World Data from Northern Thailand Kirsty Andresen, London School of Hygiene and Tropical Medicine	
P403	Inspection findings from Chinese clinical trials: Enhancing quality management in Real-World studies Yaqun Fu, Epidemiology Asia Pacific Unit, Biostatistics and Research Decision Sciences (BARDS), MSD R&D Co., Ltd	
P404	Multimodal spectral and thermal assessment of packaging for photosensitive pharmaceuticals Dagmara Kuca, Medical University of Silesia	
P405	Establishing sex-age-specific TSH and FT4 reference intervals among adults in Hong Kong Jiawen Lu, The Hong Kong Polytechnic University	
P406	Impact of pesticides knowledge and practice on quality of life among farmers Tejashree M U, Manipal College of Pharmaceutical Sciences	
P407	What makes a drug innovative: Innovation indicators and FDA expedited programs Jieun Park, Ewha Womans University	
P408	Treatment-resistance phenotypes in administrative healthcare data: A scoping review Sam Wade, Monash University	
P409	Global landscape and time trends of stem cell clinical trials in ClinicalTrials.gov Li Xie, Shanghai Jiao Tong University	
P410	Systematic review of comparative clinical studies of generic and originator drugs Cai Yuran, Sichuan University	

將今晚の自然入睡
今晚の好眠
交給我

#你需要
自然入睡嗎

#可以不依賴?

#如何無反彈

DAYVIGO® 達衛眠® Eisai

Lemborexant

28 film-coated tablets

Each tablet contains 5 mg of lemborexant.

Prescription Drug
處方藥物

5 mg

28 Tablets

Eisai

藥材(香港)有限公司 Eisai (Hong Kong) Co., Ltd.
地址: 北角電氣道369號樓上商業中心208室
電話: (852) 2516-6128 傳真: (852) 2561-5042

請於使用前詳閱產品說明書 | 內容僅供參考, 有關個別病人治療方案, 請諮詢專科醫生查詢
HK-DG-13-002 (Sep 2025)

Thank you to our sponsors

Supporting Partner



Gold Sponsor



Silver Sponsors



ACPE 2025 is hosted by



Conference Secretariat

Expert Events, Brisbane, Australia | acpe@expertevents.com.au